China International Capital Corp

China International Capital Corp (CICC) raised $1bn from a three year floating rate bond on Monday, appealing to investors because of its strong credentials and name recognition, said bankers on the deal.

There was a burst of activity from Chinese pharmaceutical and biotechnology companies in the equity capital markets this week, as the sector took centre stage following the spread of a flu-like virus that has already claimed lives on the mainland. Jonathan Breen reports.

Sino Biopharmaceutical issued a zero coupon convertible bond on Wednesday, boosting the size to €750m as demand poured in from across Asia, Europe and the US, according to multiple sources close to the deal.

Chinese real estate developer Beijing Capital Land has raised HK$925.3m ($119.1m) from the H-share portion of a three-tranche rights issue.

Elite Commercial Real Estate Investment Trust has opened books for an IPO that could raise up to £130.7m ($169.7m), according to a source familiar with the matter.

A flurry of accelerated bookbuilds hit the Hong Kong market on Thursday night as issuers and investors squeeze through the last window for fundraising before companies go into earnings blackout and the Chinese New Year holidays.

China’s challenger to Starbucks, Luckin Coffee, has raised $979.6m after increasing the size of a combined sale of new shares and a convertible bond, the first tap of the ADS equity-linked market in 2020.

Improved market conditions and a more realistic pricing target allowed a failed deal in December from a local government financing vehicle (LGFV) to sail through this week, while two more property developers joined an offshore funding spree from the sector.

Jiumaojiu International Holdings bagged HK$2.2bn ($283.3m) this week from its IPO after bulging retail and institutional books pushed pricing to the top of guidance, according to a source familiar with the matter.

Luckin Coffee, China’s answer to Starbucks, has launched a combined follow-on offering and convertible bond issue to raise up to $821m.

The Shanghai Stock Exchange’s Star board is set to welcome two new companies, as Waison Holdings and Shanghai Electric Group plan to list subsidiaries on China's Nasdaq-style market.

I-Mab, a China-based biopharmaceutical company, has kicked off the roadshow for its up to $111.1m Nasdaq IPO, more than two months after filing draft documents with the US regulator.